Please ensure Javascript is enabled for purposes of website accessibility

Exact Sciences Acquires 2 Cancer Diagnostic Companies

By Brian Orelli, PhD - Updated Mar 3, 2020 at 4:11PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The companies will complement its precision oncology products.

Exact Sciences (EXAS 6.89%) is on a bit of an acquisition spree. Having closed its acquisition of Genomic Health in November, the diagnostic test maker announced it was buying two privately held cancer diagnostic companies, Paradigm Diagnostics and Viomics, on Tuesday after the closing bell.

Paradigm Diagnostics has a genomic profiling test for patients with advanced, refractory, or recurrent cancer to help doctors determine which drug the patient should be treated with next. The company has already gained Medicare coverage for the test. There's plenty of competition in the space, but Exact claims that Paradigm's test "requires smaller sample requirements and delivers faster results."

Viomics has DNA sequencing capabilities and has been identifying biomarkers that could be used to detect cancer. Assuming the research plays out, Exact plans to use the biomarkers in future tests it may offer.

Woman holding hands with a woman in a hospital bed

Image source: Getty Images.

Both companies will fit nicely with the breast and prostate cancer tests that Exact acquired in its deal for Genomic Health. The acquisitions should produce cost synergies since Exact can use its existing sales force to promote the new products.

Exact didn't disclose financial terms of the acquisitions, so it's safe to assume they were small deals that may not be meaningful to revenue for a few years. That's in stark contrast to Genomic Health, which has had a huge impact on Exact's revenue.

Management is predicting that 2020 revenue from its precision oncology products -- the old Genomic Health products -- will contribute about $490 million to the approximately $1.63 billion that the whole company will generate.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Exact Sciences Corporation Stock Quote
Exact Sciences Corporation
EXAS
$45.15 (6.89%) $2.91

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
336%
 
S&P 500 Returns
115%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 06/26/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.